Chong Kun Dang Presents Preclinical Results of Novel Bispecific Antibody Cancer Drug at US Conference

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang announced on the 22nd that it will present the preclinical results of the anti-cancer bispecific antibody biopharmaceutical ‘CKD-702’ at the American Association for Cancer Research (AACR) Annual Meeting.

The preclinical study being presented was conducted as a monotherapy in a non-small cell lung cancer animal model to confirm the anti-cancer efficacy and mechanism of action of CKD-702.

The study results showed that CKD-702 exhibited anti-cancer effects by simultaneously inhibiting the hepatocyte growth factor receptor (c-Met) and the epidermal growth factor receptor (EGFR), both essential for cancer growth and proliferation in cancer cell lines. Notably, it was found to be effective even in animal models resistant to existing c-Met and EGFR targeted tyrosine kinase inhibitors (TKIs).

CKD-702 binds simultaneously to c-Met and EGFR, blocking cancer cell proliferation signals and reducing the number of both receptors, thereby exhibiting anti-cancer effects. Additionally, it induces antibody-dependent cellular cytotoxicity (ADCC), which helps immune cells exert cytotoxic functions against cancer cells. These three mechanisms of action are expected to overcome resistance issues associated with targeted anticancer drugs, making CKD-702 a promising new drug.

Chong Kun Dang is currently conducting a Phase 1 clinical trial in South Korea with non-small cell lung cancer as the indication and plans to expand the application to gastric cancer, colorectal cancer, liver cancer, and others for global clinical trials in the future.

A representative from Chong Kun Dang stated, “Bispecific antibodies, which are attracting attention as next-generation anticancer agents, have only one approved drug worldwide, so the preclinical results of CKD-702 are highly significant. We will expand indications to cancers with high unmet needs and accelerate domestic and international clinical trials to develop CKD-702 as a global innovative new drug.”

This content was produced with the assistance of AI translation services.